Investing in stocks that promise longevity and consistent returns can be challenging, particularly in a rapidly evolving market. However, certain companies in the healthcare sector exhibit the resilience and growth potential necessary to thrive over time. Bristol Myers Squibb and Medtronic stand out as two such companies, offering not only robust businesses but also attractive dividend programs.
Bristol Myers Squibb: A Leader in Pharmaceuticals
Bristol Myers Squibb is a prominent player in the pharmaceutical industry, recognized for its extensive portfolio of therapeutic products. The company has historically excelled in oncology, with ten of its products generating over $1 billion in sales last year. While some of its older medications are experiencing declining sales due to patent expirations, Bristol Myers Squibb is strategically positioned to address these challenges.
The company has a strong pipeline of newer therapies designed to offset the loss of revenue from expiring patents. Notably, it faces critical patent cliffs by the end of the decade for its top-selling drugs, Eliquis and Opdivo. To mitigate the impact of these expirations, Bristol Myers Squibb is introducing a subcutaneous formulation of Opdivo, making it easier and faster for patients to receive treatment.
Growth Potential Amidst Challenges
Despite the impending patent losses, Bristol Myers Squibb’s commitment to innovation ensures that it remains competitive. The company has a history of overcoming obstacles, and its focus on developing new products positions it well for sustainable growth. As newer therapies gain traction, they are expected to significantly contribute to the company’s revenue and earnings.
The appeal of Bristol Myers Squibb extends beyond its growth potential. With a forward dividend yield of 4%, it is an attractive option for income-focused investors. The company has increased its dividend payout by an impressive 65.8% over the past decade. For shareholders willing to reinvest dividends, this stock can serve as a reliable source of long-term returns, even if it may be perceived as “boring.”
Medtronic: Innovating in Medical Devices
Medtronic is a leader in the medical device sector, known for its innovative products that address various health conditions. The company’s portfolio includes cutting-edge technologies, such as pulsed field ablation (PFA), which it helped pioneer for specific heart conditions. This innovative approach positions Medtronic as a market leader in this area.
The company consistently launches new products, contributing to steady revenue and earnings growth. A significant recent development is the Hugo system, a robotic-assisted surgery device approved for urologic procedures. With the robotic-assisted surgery market being relatively underpenetrated, Medtronic has substantial opportunities for expansion as it seeks new applications for this technology.
Strategic Business Changes
Medtronic is also undergoing a strategic transformation by separating its diabetes care unit into an independent corporation. This move is designed to enhance overall margins, as the diabetes segment has historically operated with lower profitability. Such initiatives signal Medtronic’s commitment to refining its business model, which is likely to yield positive results in the future.
A Strong Dividend History
What further distinguishes Medtronic is its robust dividend program. The company has a remarkable track record, having increased its dividend payouts annually for 48 consecutive years. This consistent growth in dividends underscores Medtronic’s resilience in various market conditions, making it an attractive choice for long-term investors seeking income.
Conclusion
Both Bristol Myers Squibb and Medtronic exemplify the characteristics of strong, enduring investments in the healthcare sector. Their commitment to innovation, coupled with robust dividend programs, positions them as reliable options for investors looking to secure steady returns over time. As the healthcare landscape evolves, these companies are likely to maintain their relevance and profitability, making them worthy additions to any long-term investment portfolio.
- Bristol Myers Squibb: Strong growth potential with a solid dividend yield of 4%.
- Medtronic: Leader in medical devices with a 48-year record of annual dividend increases.
- Strategic Innovations: Both companies are focused on innovation to offset challenges from patent expirations or market changes.
- Long-term Investment: Ideal for investors seeking consistent returns and income.
- Healthcare Resilience: These companies demonstrate the ability to navigate changing market dynamics effectively.
Read more → www.fool.com